Dermatomyositis: diagnosis, evaluation and management.

Area of Science:

• Rheumatology
• Dermatology
• Internal Medicine

Background:

• Dermatomyositis (DM) is a systemic autoimmune condition primarily affecting the skin and muscles.
• Adult DM is notably associated with an increased risk of malignancy, necessitating thorough patient evaluation.
• Systemic involvement can extend to esophageal, pulmonary, and cardiac systems.

Purpose of the Study:

• To provide a comprehensive overview of dermatomyositis, including its systemic manifestations.
• To outline current therapeutic strategies for both the myopathic and cutaneous components of DM.
• To discuss prognostic factors and potential long-term sequelae in DM patients.

Main Methods:

• Review of existing literature on dermatomyositis diagnosis, treatment, and prognosis.
• Synthesis of information regarding the management of muscle and skin symptoms.
• Analysis of factors influencing patient outcomes, including comorbidities and malignancy association.

Main Results:

• Effective treatments for DM myopathy include corticosteroids, immunosuppressives, biologics, and immune globulin.
• Cutaneous manifestations are managed with sun protection, topical corticosteroids, antimalarials, and methotrexate.
• Prognosis is generally favorable but can be complicated by malignancy, severe weakness, or cardiopulmonary dysfunction.

Conclusions:

• Dermatomyositis requires a multidisciplinary approach, addressing both its primary symptoms and potential systemic complications.
• While treatments can control disease activity, residual weakness remains a concern for many patients.
• Vigilant monitoring for associated conditions, particularly malignancy, is essential throughout the patient's care journey.